Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
Findings of the review showed that continuous insulin infusion, coupled with standard oral lipid lowering therapies, successfully treated the hypertriglyceridemia.
Researchers conducted a patient-level pooled analysis from phase 3 trials of inclisiran in patients with familial hypercholesterolemia or ASCVD.
Observational studies using Mendelian randomization have demonstrated a causal relationship between normal range thyroid stimulating hormone (TSH) levels and blood lipids. In this featured study, researchers attempt to show a causal relationship between thyroid function and lipids.
Study authors performed a retrospective review of a thyroid cancer cohort to evaluate the association between metabolic health and severity of thyroid cancer.
A team of investigators conducted a large retrospective, cohort study to assess whether a longitudinal link exists between H pylori infection and the risk of developing dyslipidemia.
Lipoprotein apheresis was associated with reduced concentrations of LDL-C and Lp(a) in patients with hyperlipoproteinemia (a) and FH on a maximally tolerated lipid-lowering regimen.
The objective was to study the incidence of acute pancreatitis, ischemic cardiovascular disease, and diabetes in hyperchylomicronemic patients with FCS and MCS compared with the general population.
In this phase 2 trial, patients with hypercholesterolemia and clinical atherosclerotic cardiovascular disease were recruited from 85 sites across 20 countries.
Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.
Poor cardiovascular outcomes are more likely in patients with elevated remnant cholesterol or triglycerides.